Belén Garijo

Belén Garijo
Merck (Darmstadt, Germany) · CC BY-SA 3.0 de · source
Name	Belén Garijo
Birth date	1960
Birth place	Madrid, Spain
Nationality	Spanish
Alma mater	Complutense University of Madrid, University of Alcalá
Occupation	Business executive, physician
Known for	CEO of Merck KGaA, Darmstadt, Chair of Merck Group Executive Board

Belén Garijo

Belén Garijo is a Spanish physician and business executive who serves as Chief Executive Officer of Merck KGaA, Darmstadt, Germany, and Chair of the Merck Group Executive Board. She has a background in medicine and health economics and rose through leadership roles at Spanish and international pharmaceutical and healthcare companies, linking clinical practice with corporate strategy. Garijo's career spans roles in hospital medicine, health technology assessment, pharmaceutical development, and corporate governance.

Early life and education

Born in Madrid, Garijo studied medicine at the Complutense University of Madrid and trained in internal medicine at hospital centers affiliated with the University of Alcalá. Early in her career she pursued postgraduate training in health economics and management, engaging with institutions such as the Spanish National Health System institutions and professional networks connected to European Commission health policy frameworks. Her medical training included exposure to clinical practice in Madrid hospitals and interactions with Spanish research organizations like the Spanish Network of Health Technology Assessment and academic departments at the Complutense University of Madrid.

Career

Garijo began her professional life as a clinician in Spanish hospitals before moving into executive roles in healthcare companies and consultancies, interacting with organizations including Roche, Novartis, and national pharmaceutical associations. She joined the Spanish pharmaceutical and healthcare sector during a period of expansion involving companies such as Grifols and collaborated with multinational firms like Pfizer and Sanofi on market access and payer strategies. Garijo later took senior management roles at Bristol-Myers Squibb-like environments and engaged with European regulatory and reimbursement stakeholders, including the European Medicines Agency and national health technology assessment bodies. Prior to her appointment at Merck KGaA, she held leadership positions in global healthcare companies that operated across Germany, France, United Kingdom, and United States markets.

Leadership at Merck KGaA and Merck Group

Garijo joined Merck KGaA, Darmstadt, a multinational science and technology company with roots dating to the 17th century, and advanced into top executive leadership amid organizational transformations comparable to those overseen by leaders at Bayer, BASF, and Roche. As CEO she has overseen strategic initiatives spanning the company's Pharmaceuticals business, Life Science tools and services divisions, and performance materials comparable to portfolios at Thermo Fisher Scientific and GE Healthcare. Her tenure included managing relationships with institutional investors such as BlackRock and Vanguard, navigating capital allocation and R&D investment decisions amid global shifts affecting companies like AstraZeneca and Johnson & Johnson. Garijo's leadership engaged with scientific collaborations and partnerships involving academic institutions including Massachusetts Institute of Technology, University of Cambridge, and Heidelberg University, and with industrial alliances akin to those between Merck KGaA and technology firms. She has directed responses to regulatory developments at agencies like the U.S. Food and Drug Administration and the European Commission, and steered corporate strategy during periods of global market volatility influencing peers such as Novo Nordisk and AbbVie.

Board memberships and affiliations

Garijo holds and has held board and advisory roles in corporate and non-profit institutions, interacting with governance bodies similar to those of Daimler, Siemens, Deutsche Bank, and international organizations including World Economic Forum initiatives. She participates in industry associations aligned with European Federation of Pharmaceutical Industries and Associations-type entities and engages with academic advisory boards at institutions such as Imperial College London and Karolinska Institutet. Her affiliations extend to multinational corporate governance networks and sustainability forums comparable to UN Global Compact and investor groups like the Institutional Shareholder Services, and she represents Merck in dialogues with supranational institutions including the Organisation for Economic Co-operation and Development.

Awards and recognition

Garijo has been recognized in rankings and awards highlighting influential women in business, akin to honors from publications like Forbes, Financial Times, and Fortune, and has appeared on lists of leading executives in the Pharmaceutical Executive and Bloomberg profiles. She has received industry awards for leadership and diversity similar to accolades granted by organizations such as Women in Pharma and European CEO forums, and has been acknowledged by business schools and professional societies including those at the IE Business School and INSEAD for contributions to corporate leadership and healthcare innovation.

Category:Spanish physicians Category:Living people Category:1960 births